Akeso, Inc.

announcement Next Day Disclosure Return HKEXPDF 16. říj 2026 před 12 dny announcement COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE HKEXPDF 16. říj 2026 před 12 dny announcement PLACING OF NEW SHARES UNDER GENERAL MANDATE HKEXPDF 14. říj 2026 před 14 dny announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026 HKEXPDF 7. říj 2026 před 21 dny interim_report 2026 INTERIM REPORT HKEXPDF 30. zář 2026 před 28 dny announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2026 HKEXPDF 3. zář 2026 před 2 měs. announcement VOLUNTARY ANNOUNCEMENT - IVONESCIMAB MEETS OS KEY SECONDARY ENDPOINT IN INTERIM ANALYSIS OF HARMONI-2 STUDY, DEMONSTRATING STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFIT VERSUS PEMBROLIZUMAB IN 1L PD-L1-POSITIVE NSCLC HKEXPDF 3. zář 2026 před 2 měs. interim_report INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 HKEXPDF 27. srp 2026 před 2 měs. announcement VOLUNTARY ANNOUNCEMENT - AK112-309/HARMONI-GI1 MET PRIMARY ENDPOINT OF OS IVONESCIMAB PLUS CHEMO DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL OS BENEFIT VERSUS DURVALUMAB PLUS CHEMO IN 1L BTC HKEXPDF 26. srp 2026 před 2 měs. announcement DATE OF BOARD MEETING HKEXPDF 17. srp 2026 před 2 měs. announcement VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE 3RD INDICATION FOR (IVONESCIMAB, PD-1/VEGF) AS 1L TREATMENT FOR SQ-NSCLC HKEXPDF 12. srp 2026 před 3 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2026 HKEXPDF 6. srp 2026 před 3 měs. announcement GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS HKEXPDF 26. čvc 2026 před 3 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2026 HKEXPDF 2. čvc 2026 před 4 měs. results_announcement POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MONDAY, JUNE 29, 2026 HKEXPDF 29. čvn 2026 před 4 měs. announcement VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR (GUMOKIMAB, AK111) HAS BEEN APPROVED BY NMPA HKEXPDF 12. čvn 2026 před 5 měs. announcement VOLUNTARY ANNOUNCEMENT - PROPOSED ON-MARKET SHARE PURCHASES APPROVED BY THE BOARD AND MANAGEMENT REFLECTING THE BOARD'S ASSESSMENT OF THE COMPANY'S INTRINSIC VALUE HKEXPDF 11. čvn 2026 před 5 měs. announcement FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, JUNE 29, 2026 HKEXPDF 5. čvn 2026 před 5 měs. announcement NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 5. čvn 2026 před 5 měs. announcement PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITORS; AND NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 5. čvn 2026 před 5 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2026 HKEXPDF 4. čvn 2026 před 5 měs. results_announcement VOLUNTARY ANNOUNCEMENT - OVER 40 STUDIES PRESENTED AT 2026 ASCO HARMONI-6 RESULTS PUBLISHED IN 2026 ASCO & THE LANCET FOR IVONESCIMAB PLUS CHEMO VS TISLELIZUMAB PLUS CHEMO IN 1L ADVANCED SQUAMOUS-NSCLC HKEXPDF 1. čvn 2026 před 5 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2026 HKEXPDF 6. kvě 2026 před 6 měs. announcement Notification Letter and Reply Form to Non-registered Holders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications HKEXPDF 29. dub 2026 před 6 měs. announcement Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications HKEXPDF 29. dub 2026 před 6 měs. esg_report 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT HKEXPDF 29. dub 2026 před 6 měs. Výroční 2025 ANNUAL REPORT HKEXPDF 29. dub 2026 před 6 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2026 HKEXPDF 8. dub 2026 před 7 měs. Výroční ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 HKEXPDF 26. bře 2026 před 7 měs. announcement DATE OF BOARD MEETING HKEXPDF 16. bře 2026 před 7 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2026 HKEXPDF 4. bře 2026 před 8 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2026 HKEXPDF 5. úno 2026 před 9 měs. announcement VOLUNTARY ANNOUNCEMENT - AKESO GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR EBRONUCIMAB INJECTION TO JUMPCAN PHARMACEUTICAL HKEXPDF 3. úno 2026 před 9 měs. announcement CONTINUING CONNECTED TRANSACTION FURTHER INFORMATION IN RELATION TO THE CONTRACT MANUFACTURING ARRANGEMENT HKEXPDF 26. led 2026 před 9 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2025 HKEXPDF 6. led 2026 před 10 měs. announcement CONTINUING CONNECTED TRANSACTIONS PURSUANT TO RULE 14A.60 OF THE LISTING RULES HKEXPDF 31. pro 2025 před 10 měs. announcement VOLUNTARY ANNOUNCEMENT - ALL APPROVED INDICATIONS OF AKESO'S 5 MARKETED DRUGS INCLUDED IN THE MOST RECENT NRDL HKEXPDF 7. pro 2025 před 11 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2025 HKEXPDF 4. pro 2025 před 11 měs. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2025 HKEXPDF 5. lis 2025 před 1 r. results_announcement VOLUNTARY ANNOUNCEMENT - HARMONI-6 RESULTS PUBLISHED IN THE LANCET & 2025 ESMO mPFS 11.14m vs 6.9m (HR=0.60, P50.0001) FOR IVONESCIMAB PLUS CHEMO VS TISLELIZUMAB PLUS CHEMO IN 1L ADVANCED SQ-NSCLC HKEXPDF 20. říj 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2025 HKEXPDF 8. říj 2025 před 1 r. interim_report 2025 INTERIM REPORT HKEXPDF 30. zář 2025 před 1 r. announcement Next Day Disclosure Return HKEXPDF 4. zář 2025 před 1 r. announcement COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES HKEXPDF 4. zář 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2025 HKEXPDF 3. zář 2025 před 1 r. announcement PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES HKEXPDF 28. srp 2025 před 1 r. announcement TERMS OF REFERENCE OF THE NOMINATION COMMITTEE HKEXPDF 26. srp 2025 před 1 r. interim_report INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 HKEXPDF 26. srp 2025 před 1 r. announcement DATE OF BOARD MEETING HKEXPDF 14. srp 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2025 HKEXPDF 6. srp 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2025 HKEXPDF 4. čvc 2025 před 1 r. results_announcement POLL RESULTS OF THE ANNUAL GENERAL MEETING AND THE EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, JUNE 30, 2025 HKEXPDF 30. čvn 2025 před 1 r. announcement FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, JUNE 30, 2025 HKEXPDF 11. čvn 2025 před 1 r. announcement NOTICE OF EXTRAORDINARY GENERAL MEETING HKEXPDF 11. čvn 2025 před 1 r. announcement PROPOSED GRANT OF SHARE OPTIONS AND RSUS TO DR. XIA AND NOTICE OF EXTRAORDINARY GENERAL MEETING HKEXPDF 11. čvn 2025 před 1 r. announcement FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, JUNE 30, 2025 HKEXPDF 8. čvn 2025 před 1 r. announcement NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 8. čvn 2025 před 1 r. announcement PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITORS; AND NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 8. čvn 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER HKEXPDF 5. čvn 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2025 HKEXPDF 4. čvn 2025 před 1 r. announcement GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS HKEXPDF 26. kvě 2025 před 1 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2025 HKEXPDF 8. kvě 2025 před 1 r. announcement Notification Letter and Reply Form to Non-registered Holders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications HKEXPDF 29. dub 2025 před 1 r. announcement Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications HKEXPDF 29. dub 2025 před 1 r. esg_report 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT HKEXPDF 29. dub 2025 před 1 r. Výroční 2024 ANNUAL REPORT HKEXPDF 29. dub 2025 před 1 r. announcement VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE 2ND INDICATION FOR IVONESCIMAB (PD-1/VEGF) AS 1L TREATMENT FOR NSCLC WITH POSITIVE PD-L1 EXPRESSION HKEXPDF 27. dub 2025 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - FDA APPROVED ANNIKO (PENPULIMAB-KCQX, PD-1) IN TWO INDICATIONS FOR COMPREHENSIVE TREATMENT OF ADVANCED NASOPHARYNGEAL CARCINOMA HKEXPDF 25. dub 2025 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - AK112-306/HARMONI-6 MET PRIMARY ENDPOINT OF PFS SUPERIORITY IVONESCIMAB PLUS CHEMO DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS VS. TISLELIZUMAB PLUS CHEMO IN 1L SQ-NSCLC HKEXPDF 23. dub 2025 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - NMPA APPROVED NDA OF (EBDAROKIMAB, IL-12/IL-23) HKEXPDF 21. dub 2025 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2025 HKEXPDF 3. dub 2025 před 2 r. Výroční ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 HKEXPDF 30. bře 2025 před 2 r. announcement DATE OF BOARD MEETING HKEXPDF 19. bře 2025 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2025 HKEXPDF 5. bře 2025 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2025 HKEXPDF 6. úno 2025 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2024 HKEXPDF 7. led 2025 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2024 HKEXPDF 4. pro 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - THE INCLUSION IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST OF CADONILIMAB AND IVONESCIMAB HKEXPDF 28. lis 2024 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2024 HKEXPDF 4. lis 2024 před 2 r. announcement Next Day Disclosure Return HKEXPDF 21. říj 2024 před 2 r. announcement COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE HKEXPDF 21. říj 2024 před 2 r. announcement PLACING OF NEW SHARES UNDER GENERAL MANDATE HKEXPDF 13. říj 2024 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2024 HKEXPDF 3. říj 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE NEW DRUG APPLICATION OF (EBRONUCIMAB, PCSK9) HKEXPDF 30. zář 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA OF (CADONILIMAB, PD-1/CTLA-4) IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR GASTRIC CANCER HKEXPDF 30. zář 2024 před 2 r. interim_report 2024 INTERIM REPORT HKEXPDF 30. zář 2024 před 2 r. results_announcement VOLUNTARY ANNOUNCEMENT - PFS HR 0.51, MPFS 11.14 MONTHS IVONESCIMAB MONOTHERAPY VS PEMBROLIZUMAB AS 1L TREATMENT OF PD-L1 POSITIVE NSCLC (AK112-303/HARMORNI-2) PHASE III RESULTS PUBLISHED AT 2024 WCLC HKEXPDF 9. zář 2024 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2024 HKEXPDF 3. zář 2024 před 2 r. interim_report INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 HKEXPDF 28. srp 2024 před 2 r. announcement DATE OF BOARD MEETING HKEXPDF 16. srp 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - AK112-303/HARMONI-2 WAS ACCEPTED AS LBA OF 2024 WCLC PRESIDENTIAL SYMPOSIUM ORAL PRESENTATION HKEXPDF 12. srp 2024 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2024 HKEXPDF 5. srp 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR IVONESCIMAB (PD-1/VEGF) MONOTHERAPY AS FIRST-LINE TREATMENT FOR NSCLC WITH POSITIVE PD-L1 EXPRESSION HKEXPDF 30. čvc 2024 před 2 r. announcement APPOINTMENT OF CHIEF FINANCIAL OFFICER HKEXPDF 22. čvc 2024 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2024 HKEXPDF 5. čvc 2024 před 2 r. announcement LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS HKEXPDF 1. čvc 2024 před 2 r. announcement CHANGE OF DIRECTORS HKEXPDF 1. čvc 2024 před 2 r. results_announcement POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON SUNDAY, JUNE 30, 2024 HKEXPDF 1. čvc 2024 před 2 r. announcement 2021 RSU SCHEME HKEXHTML 14. čvn 2024 před 2 r. announcement SHARE OPTION SCHEME HKEXHTML 14. čvn 2024 před 2 r. announcement FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON SUNDAY, JUNE 30, 2024 HKEXPDF 6. čvn 2024 před 2 r. announcement NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 6. čvn 2024 před 2 r. announcement PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; PROPOSED AMENDMENTS TO THE SHARE OPTION SCHEME; PROPOSED RE-APPOINTMENT OF AUDITORS; AND NOTICE OF ANNUAL GENERAL MEETING HKEXPDF 6. čvn 2024 před 2 r. announcement (I) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME AND THE SHARE OPTION SCHEME; AND (II) TERMINATION OF THE PRE-IPO RSU SCHEME HKEXPDF 5. čvn 2024 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2024 HKEXPDF 5. čvn 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - AMENDMENT TO THE LICENSE AGREEMENT FOR IVONESCIMAB (PD-1/VEGF) WITH SUMMIT THERAPEUTICS INC. HKEXPDF 3. čvn 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT - AK112-303 REACHED PRIMARY ENDPOINT OF PFS SUPERIORITY IVONESCIMAB DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL SUPERIORITY AS FIRST LINE MONOTHERAPY FOR PD-L1+ NSCLC VERSUS PEMBROLIZUMAB, HAZARD RATIO SIGNIFICANTLY BETTER THAN EXPECTED HKEXPDF 31. kvě 2024 před 2 r. announcement VOLUNTARY ANNOUNCEMENT (IVONESCIMAB INJECTION) OBTAINED NMPA'S MARKETING APPROVAL IN CHINA HKEXPDF 24. kvě 2024 před 2 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2024 HKEXPDF 7. kvě 2024 před 2 r. announcement Notification Letter and Reply Form to Non-registered Holders - Notice of Publication of 2023 Annual Report HKEXPDF 29. dub 2024 před 2 r. announcement Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of 2023 Annual Report HKEXPDF 29. dub 2024 před 2 r. esg_report 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT HKEXPDF 29. dub 2024 před 2 r. Výroční 2023 ANNUAL REPORT HKEXPDF 29. dub 2024 před 2 r. announcement EXCEEDED 2023 ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS MASTER MATERIALS AND SERVICES PROCUREMENT AGREEMENT WITH CHIA TAI TIANQING IN RELATION TO CLINICAL TRIAL OF PENPULIMAB (PD-1 MONOCLONAL ANTIBODY, AK105) HKEXPDF 28. dub 2024 před 3 r. announcement VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER HKEXPDF 24. dub 2024 před 3 r. announcement Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications HKEXPDF 8. dub 2024 před 3 r. announcement Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications HKEXPDF 8. dub 2024 před 3 r. announcement Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024 HKEXPDF 5. dub 2024 před 3 r. announcement Next Day Disclosure Return HKEXPDF 28. bře 2024 před 3 r. announcement COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE HKEXPDF 28. bře 2024 před 3 r.